In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA". Here are the key studies discussed:1. ASH choosing wisely: https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely 2. International Consensus Classification (ICC): https://pubmed.ncbi.nlm.nih.gov/35767897/ 3. WHO classification 2022: https://pubmed.ncbi.nlm.nih.gov/35732829/ 4. IPSS-M: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008 5. Romiplostim in MDS: https://pubmed.ncbi.nlm.nih.gov/29396092/ 6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200034 7. Luspatercept in MDS: https://www.nejm.org/doi/full/10.1056/nejmoa1908892 8. Lenalidomide in MDS: https://ascopubs.org/doi/10.1200/JCO.2015.66.0118https://pubmed.ncbi.nlm.nih.gov/21753188/ 9.Iron chelation therapy in MDS: https://pubmed.ncbi.nlm.nih.gov/32203980/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related